Sugi Predict

Sugi Predict / Compounds / SCHEMBL10137609

SCHEMBL10137609

SCHEMBL10137609

CC(C)(C)OC(=O)[C@@H]1C=CCN1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 1/20 0.38
▸ CTSK P43235 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ACE P12821 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NR1H2 P55055 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31375026 1.00 PREP (0.38) PREPCTSKMAPK1CHRM2CHRM1
SCHEMBL3546343 0.90 PTPN1 (0.39) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL2559556 0.90 PTPN1 (0.39) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL3546340 0.90 PTPN1 (0.39) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL25175295 0.87 ACE (0.47) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL629586 0.87 ACE (0.47) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL629585 0.87 ACE (0.47) PREPCTSKCHRM2CHRM1CHRM3
SCHEMBL13519523 0.86 NFKB1 (0.41) PREPCTSKACELMNANPSR1
SCHEMBL6789639 0.86 NFKB1 (0.41) PREPCTSKACELMNANPSR1
SCHEMBL3915923 0.85 PREP (0.37) PREPCTSKCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605386-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-08-27 — — EP disclosed
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
EP-4551569-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 — — WO disclosed
CN-119306790-A Amide derivative, composition and use thereof 深圳市塔吉瑞生物医药有限公司 2025-01-14 — — CN disclosed
CN-118159548-A Antiviral compounds 安力高医药股份有限公司 2024-06-07 — — CN disclosed
US-20240182444-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-06 — — US disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 — — EP disclosed
WO-2024086111-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-04-25 — — WO disclosed
WO-2024081318-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
US-11851422-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. 2023-12-26 — — US disclosed
WO-2023116734-A1 FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) 2023-06-29 — — WO disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 — — CN disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 — — EP disclosed
US-20230093249-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-03-23 — — US disclosed
WO-2023283256-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2023-01-12 — — WO disclosed
WO-2022087630-A1 INHIBITORS OF AMINO ACID TRANSPORT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed
US-RE43298-E1 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2012-04-03 — — US disclosed
US-8067379-B2 Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2011-11-29 — — US disclosed
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PREP 294/4885CTSK 1688/4885MAPK1 1561/4885
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS HPN, TMPRSS15, VIP PREP 15/4885CTSK 243/4885MAPK1 3042/4885
US-20240182444-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PREP 294/4885CTSK 1688/4885MAPK1 1561/4885
US-20230093249-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PREP 294/4885CTSK 1688/4885MAPK1 1561/4885
US-11851422-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 PREP 294/4885CTSK 1688/4885MAPK1 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.